Claims for Patent: 8,388,952

Summary for Patent: 8,388,952

Title:	Botulinum toxin compositions and methods
Abstract:	Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a Clostridial neurotoxins, to treat various medical conditions, such as overactive bladder, benign prostatic hyperplasia, hyperhidrosis, for example.
Inventor(s):	Gaylis; Franklin D. (La Mesa, CA), Blumenfeld; Andrew M. (Del Mar, CA)
Assignee:	Allergan, Inc. (Irvine, CA) Gaylis; Franklin D. (La Mesa, CA)
Application Number:	12/032,013
Patent Claims:	1. A method for treating a patient having a cholinergically-influenced disorder, comprising the steps of: a) administering via instillation a first composition containing an extracellular matrix digesting enzyme to a luminal surface area of the patient; b) allowing sufficient time to pass for the extracellular matrix digesting enzyme to diffuse through the surface area and to a target; c) administering a second composition containing a botulinum toxin to the surface area; and d) allowing sufficient time for the botulinum toxin to diffuse through the surface area and to the target, thereby alleviating at least one symptom associated with the cholinergically-influenced disorder and treating the patient having a cholinergically-influenced disorder wherein the cholinergically-influenced disorder is a urologic disorder selected from the group consisting of a bladder disorder and a prostate disorder. 2. The method of claim 1, wherein the luminal surface area is urinary bladder luminal surface area. 3. The method of claim 2, wherein the target is a detrusor muscle. 4. The method of claim 2, wherein administration of the composition containing the botulinum toxin is by instillation into the bladder and the target is a detrusor muscle. 5. The method of claim 2, wherein administration of the botulinum toxin is accomplished by less than 20 injections of the second composition into the bladder wall of the bladder and the target includes a detrusor muscle. 6. The method of claim 5, wherein administration of the second composition containing the botulinum toxin accomplished by less than 10 injections into the bladder wall. 7. The method of claim 5, wherein administration of the second composition containing the botulinum toxin accomplished by performing between 1 and 5 injections into the bladder wall. 8. The method of claim 3, wherein the botulinum toxin is selected from the group consisting of botulinum toxin type A, B, C.sub.1, D, E, F and G. 9. The method of claim 3, further comprising the steps of emptying the bladder prior to step (a), emptying the bladder after step (b) and emptying the bladder after step (d). 10. The method of claim 1, wherein the bladder disorder is selected from the group consisting of overactive bladder, hypertrophied bladder neck and detrusor hyperreflexia. 11. The method of claim 1, wherein the prostate disorder is selected from the group consisting of benign prostatic hyperplasia, prostatitis and prostate cancer. 12. The method of claim 1, further comprising the steps of optionally removing the first composition after step (b) and optionally removing the second composition after step (d). 13. A non-injection method for treating a urologic disorder in a patient in need thereof, comprising the steps of: a) instilling a first composition containing hyaluronidase into urinary bladder of the patient in order to contact a bladder luminal surface area, having a glycosaminoglycan layer, to the first composition; b) maintaining the first composition within the bladder to allow sufficient time to pass such that hyaluronidase interacts with the glycosaminoglycan layer and diffuses through the bladder luminal surface area; c) optionally draining the first composition from the bladder; d) instilling a second composition containing a botulinum toxin type A to the bladder in order to contact the bladder luminal surface area previously contacted by the previously instilled and optionally removed first composition; and e) retaining the instilled second composition for a sufficient time within the bladder so that a sufficient amount of botulinum toxin type A therein diffuses through the bladder luminal surface area and to at least one layer of the muscularis propria, and optionally, draining the second composition from the bladder, thereby alleviating at least one symptom associated with the urologic disorder and treating the urologic disorder of the patient in need thereof. 14. The method of claim 13, wherein the urologic disorder is selected from the group consisting of overactive bladder, hypertrophied bladder neck and detrusor hyperreflexia. 15. The method according to claim 8, wherein the botulinum toxin is a botulinum toxin type A. 16. The method according to claim 15, wherein the amount of botulinum toxin type A is between about 20 units and about 2750 units. 17. The method according to claim 8, wherein the at least one extracellular matrix digesting enzyme is selected from the group consisting of a hyaluronidase, a tissue plasminogen activator and a collagenase. 18. The method according to claim 16, wherein said extracellular matrix digesting enzyme is hyaluronidase.

Details for Patent 8,388,952

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2027-02-15
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2027-02-15
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2027-02-15
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2027-02-15